Trials / Completed
CompletedNCT04144517
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 Without Having Achieved a Complete Remission
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Mural Oncology, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study was to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who had previously received anti-PD-(L)1 therapy but who had not achieved a CR.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nemvaleukin Alfa | Nemvaleukin alfa IV infusion. |
| DRUG | Pembrolizumab | Pembrolizumab IV infusion. |
Timeline
- Start date
- 2020-02-05
- Primary completion
- 2021-10-08
- Completion
- 2022-01-07
- First posted
- 2019-10-30
- Last updated
- 2024-10-16
- Results posted
- 2024-10-16
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04144517. Inclusion in this directory is not an endorsement.